Monday, October 5, 2026

Amkor Posts Record Earnings as SK Hynix Locks In AI-Memory Deals Despite Chip Stock Selloff

Semiconductor fundamentals are pulling away from Wall Street sentiment: Amkor Technology reported record earnings and SK hynix secured new AI-memory supply agreements even as leveraged AI-infrastructure ETFs fell sharply from highs. GlobalFoundries picked up a $300 million CHIPS Act award plus a government equity stake, while Skyworks and Qorvo named joint leadership ahead of their merger and Kalray struck an AI-networking partnership with Bull.

LM Salvado

August 11, 2026

Amkor Posts Record Earnings as SK Hynix Locks In AI-Memory Deals Despite Chip Stock Selloff
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Amkor Technology posted record earnings in its latest quarter, even as AI infrastructure and semiconductor stocks sold off broadly.5 Leveraged ETFs tracking the sector are down sharply from their recent highs, but the manufacturing side of the chip supply chain is showing no comparable strain.

SK hynix has locked in new AI-memory supply agreements, reinforcing demand for the high-bandwidth memory that powers AI data centers.1 The commitments suggest chipmakers are still racing to keep pace with AI buildout even as investors question whether capital spending levels are sustainable.

GlobalFoundries received a $300 million CHIPS Act award alongside a government equity stake, adding public money to the push to expand US-based chip manufacturing capacity.3 The award lands as foundries face pressure to scale output for AI accelerators and specialty chips without the multi-year lead times that have constrained supply in past cycles.

Consolidation is reshaping the supply base too. Skyworks and Qorvo announced their expected joint leadership team ahead of a planned merger, with Bob Bruggeworth citing a partnership that has shaped their integration planning "from the very beginning."2 The deal combines two RF-chip makers as demand shifts toward AI-capable connectivity hardware.

Kalray, a French chipmaker, struck a partnership with Bull to develop high-speed networking technology for next-generation AI and high-performance computing infrastructure. CEO Éric Baissus said the collaboration aims to deliver "increased performance, greater flexibility and improved efficiency" as AI reshapes infrastructure needs across sectors.4

Separately, Safe Superintelligence raised $5 billion in a round backed by Nvidia, underscoring continued capital flowing into AI development even as public semiconductor equities wobble. The divergence points to a split market: physical supply chains for AI chips are still tightening in favor of demand, while investor sentiment around the stocks that supply them has turned cautious.

Apple's leadership transition from Tim Cook to John Ternus adds a further layer of structural change atop a sector already absorbing consolidation and new capacity commitments.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 18, 2026
    Allegro MicroSystems Appoints Brian White to its Board of Directors
  2. [2]Press releaseGlobeNewswire· July 23, 2026
    AMD and Cerebras Announce Industry-Leading Ultra-Low-Latency and High Throughput AI Inference Solution
  3. [3]Press releaseGlobeNewswire· July 28, 2026
    BULL ET KALRAY S'ASSOCIENT POUR DÉVELOPPER LA PROCHAINE GÉNÉRATION DE RÉSEAUX À HAUTE VITESSE POUR L'ÈRE DE L'IA
  4. [4]News articleIEEE Spectrum
    Finding Success in Industry as a Chip Designer
  5. [5]Press releaseGlobeNewswire· July 29, 2026
    GlobalFoundries signs letter of intent with the U.S. Department of Commerce for a $300 million award to accelerate U.S. silicon photonics leadership
  6. [6]News articleYahoo Finance· July 26, 2026
    Nvidia just locked down deal that changes AI race
  7. [7]News articleYahoo Finance· June 2, 2026
    Phison Collaborates with Intel to Bring Larger Local AI Workloads to Intel AI PC Platforms
  8. [8]News articleYahoo Finance· July 28, 2026
    Skyworks and Qorvo Announce Expected Leadership Team for Combined Company
  9. [9]Press releaseGlobeNewswire· July 13, 2026
    Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results
  10. [10]News articleNasdaq· July 28, 2026
    Stocks Mixed on Earnings Results and Weakness in Chipmakers
  11. [11]News articleYahoo Finance· June 7, 2026
    USD Implodes 17% And June 8th Could Be Worse
  12. [12]Press releaseGlobeNewswire· July 1, 2026
    VSORA enters a new phase, as Ardian joins its shareholder base

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com